By Exec Edge Editorial Staff
Biopharma company Ocean Biomedical (Nasdaq: OCEA) began trading publicly today after merging with a SPAC called Aesther Healthcare Acquisition Corp. (Nasdaq: AEHA).
Ocean Biomedical is focused on the commercialization of assets from research universities and medical centers.
The company’s core portfolio is focused on oncology, pulmonary fibrosis and infectious disease. Each include new target discoveries that will enable drug and vaccine candidates, developed through past and ongoing grants.